No Panic At Newron Over Delayed Schizophrenia Drug Trial

While the markets reacted badly to the news Newron Pharmaceuticals SPA is to delay starting the pivotal program for its closely watched schizophrenia therapy evenamide, the Italian-headquartered drugmaker is confident that concerns raised by the US Food and Drug Administration over central nervous system events seen in animals can be allayed quickly.

Newron received a communication from the FDA indicating concern on findings from a recently completed toxicity study in rats as well as CNS events at higher doses in dogs, and...